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Abstract
Background: Quantitation of HIV-RNA is critically important for diagnosis, prognosis, treatment, monitoring and
assessment of infectivity in HIV-1 infection. The objective of this study was to assess performance characteristics of
the Aptima HIV-1 Quant Dx assay (Aptima), a new transcription mediated amplification (TMA), fully integrated and
automated assay from Hologic Inc., San Diego, CA, USA.
The analytical sensitivity, analytical specificity, precision and detection of HIV-1 subtypes were tested based on
commercially available international standards or panels. A selected group of 244 anti-HIV-1 (+) plasma samples was
used for comparison with Roche COBAS Ampliprep/COBAS TaqMan HIV- 1 test v2.0 (Roche CAP/CTM), (Roche
Molecular Systems, Pleasanton, CA).
Results: The 50 and 95 % limit of detection were estimated at 4.9 (95 % CI 3.9–5.7) and 17.6 (15.2–21.2) IU/mL
respectively. The specificity was found 99.83 (99.06–99.97) %. The standard deviations and coefficient of variations
for panels with 50 and 100 copies/mL (1.7 and 2 log copies/mL) were 0.14 log copies/mL (8.67 %CV) and 0.18 log
copies/mL (9.91 %CV) respectively. The detection rate for Aptima and Roche assays was 220/244 (90.2 %) and 217/
244 (88.9 %) respectively.
Conclusion: The Aptima assay is a sensitive, specific, precise and accurate test for measuring HIV-1 viral loads and
for the detection of HIV-1 infections.
Background
Quantitation of HIV-RNA (viral load) has proven
clinical utility in the diagnosis, prognosis, treatment,
monitoring and the assessment of infectivity in HIV-1
infected patients [1–4].
HIV-1 is highly heterogeneous with Group M viruses re-
sponsible for the majority of HIV-1 infections worldwide.
They are subdivided into nine subtypes (A-D, F-H, J, K)
and numerous circulating recombinant forms (CRFs). Due
to human movements and the recombination events the
HIV-1 diversity is gradually increasing posing a challenge
in the validity of viral load assays [5].
There are a number of commercially available viral
load assays which are mainly based on real-time PCR
[6–11]. These assays offer varying levels of automation
based on dedicated hardware and software, including au-
tomated result interpretation as well as high throughput.
The Aptima HIV-1 Quant Dx assay (Hologic Inc. San
Diego, CA, USA) is a fully integrated and automated
assay for use on the Panther System. At present, the test
is not approved for use in the US but is CE-IVD certified
for the detection and quantitation of HIV-1. It utilizes
transcription mediated amplification (TMA) involving
target capture, target amplification by TMA and real-
time detection of amplicons by fluorescent probes in a
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single tube. The Aptima HIV-1 Quant Dx assay requires
only 0.5mL of sample per reaction with a dead volume
as little as 0.2 mL.
The aim of this study was to assess the analytical perform-
ance characteristics of Aptima assay using commercially




Linearity of HIV-1 subtype B across the assay’s dynamic
range was assessed using AcroMetrix HIV-1 panel from
Life Technologies (Catalog number 950470 batch number
400716). This panel has 1 HIV negative panel member and
6 HIV-1 positive panel members with concentrations ran-
ging from 1e2 to 5e6 copies/mL. The recovered concentra-
tion of each panel member was compared to the
concentration value provided by the vendor. The linearity
of the various subtypes of HIV-1 was confirmed by testing
5–7 dilutions of clinical specimens (HIV subtypes A1, B, C,
F1 and CRF02-AG) and cultured isolates of HIV (subtypes
G and A/E and group O and N). The dilutions tested for
clinical specimens targeted 1e2, 5e2, 1e3, 1e4 and 1e5 cop-
ies/mL. The concentration and available volume of the clin-
ical sample stocks did not permit testing concentrations
above 1e5 copies/mL. For the clinical isolates two add-
itional dilutions at 1e6 copies/mL and 5e6 copies/mL were
also tested.
Analytical sensitivity (limit of detection)
One vial of 2nd WHO international standard for HIV-1
(NIBSC code 97/650) was reconstituted according to
manufacturer’s instructions. The sample was diluted in
HIV-1 negative plasma to concentrations ranging from 0
to 40 IU/mL (0, 5, 10, 15, 20, 25, 30 and 40 IU/mL).
Each panel member was tested on 3 Panthers with 3 re-
agent lots of Aptima HIV-1 assay reagent. Ten replicates
were tested for each concentration with each reagent lot
on each Panther (total 90 replicates per concentration).
Probit analysis was performed with the Aptima results
using SAS software to calculate the 50 and 95 % detec-
tion rates.
Analytical specificity
Specificity was assessed by testing 600 plasma specimens
collected from people who were not infected with HIV-
1. Testing was conducted with 2 reagent lots of Aptima
assay reagents with 300 specimens being tested per
reagent lot. Testing was distributed across 3 Panther
instruments. All samples which gave reactive results
(<1.47 log copies/mL detected or quantitative result or
>7 log copies/mL) were considered as false positives in
Aptima.
Precision, reproducibility and repeatability
Within-run repeatability and between-run reproducibility
of the Aptima assay was assessed by testing 8 dilutions of
HIV-1 in negative plasma ranging in concentration from
50 to 107 copies/mL. Each panel was tested on 3 Panthers
with 3 Aptima reagent lots by three operators to a total of
27 runs. Three replicates of each panel were tested in each
run. Results from all valid replicates were used for assess-
ment of precision using SAS statistics software.
Genetic variability and subtype detection
Subtype detection was assessed using the German NRC
subtype panel composed of 21 members of which 18
belong to group M (2x A, 2x B, 2x C, 3x D, 2x
CRF01_AE, 2x F, 1x G, 1x H, 1xG/H, 2x CRF02_AG), 2
to group O and 1 to group N. These panels were manu-
factured by National Resource Center using virus iso-
lates originally obtained from the NIH AIDS Research
and Reference Reagent Program, USA, or from the
Programme EVA Centre for AIDS Reagents, NIBSC, UK.
These viruses were cultivated on cells and supernatants
were diluted in HIV-negative plasma to a concentration
of approximately 100,000 HIV-1 RNA copies/mL. The
isolates were quantified using the Roche CAP/CTM and
Abbott RealTime HIV-1 (Abbott RT) assays. One repli-
cate of each subtype panel was tested in the Aptima
assay and results were compared to the Roche CAP/
CTM and Abbott RT results provided by the vendor.
This three-way comparison allowed for any results dif-
fering by more than 0.5 log copies/mL to be resolved.
Assay comparison
Assessment of agreement with an established commer-
cially available method was undertaken (Roche CAP/
CTM). The Roche CAP/CTM assay targets the gag and
LTR regions [12]. The assay uses at least 1 mL of speci-
men and reports quantifiable HIV-1 results over the
range of 20 to 10,000,000 copies/mL [12]. The Aptima
assay targets the pol and LTR regions. The assay uses
0.5 mL of specimen plus a minimum 0.2 ml dead vol-
ume and reports quantifiable HIV-1 results over the
range of 30 to 10,000,000 copies/mL [13]. Both Aptima
and Roche assays report specificity of 100 % in their re-
spective package inserts [12, 13]. Two hundred forty-
four patient plasma anti-HIV-1 (+) samples were col-
lected, aliquoted and frozen. Samples were selected
based on an historical HIV viral load result based on
Roche AmpliPrep/COBAS Taqman HIV-1 to provide
results across the range of both Roche and Aptima as-
says. One replicate of each sample was tested in Aptima
and Roche assays following the manufacturer’s instruc-
tions. One hundred seventy-four samples which had
quantitative results in both assays were used for linear
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regression and Bland-Altman analysis. These included
different HIV-1 subtypes and recombinants.
Statistical methods
The 50 and 95 % positivity rates were estimated using
Probit analysis using the normal model and analysis soft-
ware from the SAS Institute Cary, NC, USA.
The method comparison simple linear regression and
Bland Altman analysis were performed using Analyse-it
Software, Leeds, United Kingdom.
Comparison of the Aptima HIV-1 results to Roche
CAP/CTM was performed using McNamara’s test with
analysis software from the SAS Institute Cary, NC, USA.
Linearity was measured using the R2 of the Pearson




As seen from Table 1 all members of the HIV-1 subtype B
AcroMetrix linearity panel, ranging in concentration from
1e2 to 5e6 copies/mL, recovered within 0.25 logs of the
target concentration. The results in Aptima were also lin-
ear for all the major groups, subtypes and recombinants
of HIV (Figs. 1 and 2). The R2 values of the plots in Figs. 1
and 2 were all above 0.999 as shown in Table 2.
Analytical sensitivity of Aptima
By use of HIV-1 2nd International WHO standards di-
luted in plasma, the 50 and 95 % limit of detection and
95 % confidence intervals (shown in brackets) were es-
timated by Probit analysis as 4.9 (3.9–5.7) and 17.6
(15.2–21.2) IU/mL, respectively (Table 3).
Analytical specificity
The combined analytical specificity using 600 HIV-1 nega-
tive specimens from two different lots was estimated
99.83 (95 % CI of 99.06–99.97 %) (Table 4).
Precision, reproducibility and repeatability
The CVs for inter-instrument, inter-operator, inter-lot,
inter-day, inter-run and intra-run variation were 0–
4.52 %, 0–1.99 %, 0–0.77 %, 0–0.35 %, 0–5.6 % and
0.44–8.14 %, respectively. The total CVs for panels of 50
copies/mL, 102, 103, 104,105, 106, 107 copies/mL were es-
timated 8.67 %, 9.91 %, 4.08 %, 1.77 %, 1.35 %, 0.92 %,
0.9 % respectively (Table 5).
Genetic variability and subtype detection using HIV-1
viral isolates
Twenty one viral isolates were used for comparison of
Aptima Roche CAP/CTM and Abbott RT. Aptima con-
sistently quantified slightly higher compared to target
values based on Roche CAP/CTM with differences ran-
ging from 0.01 to 0.79 log copies/mL (Table 6). The dif-
ferences between Aptima and Abbott RT results ranged
from −0.12 to 1.04 log copies/mL.
Comparison of Aptima with Roche CAP/CTM using clinical
samples
Aptima quantified 220/244 (90.1 %) and Roche 217/244
(88.9 %) of the clinical samples. Eleven samples were
Roche (+), Aptima (−) and 14 samples Aptima (+), Roche
(−) (Table 7). One hundred seventy four samples were
quantified by both methods (McNemar’s p = 0.5485).
Linear regression analysis showed excellent correlation
between Aptima and Roche (R2 = 0.971). The slope was
1.06 (Fig. 3).which was statistically significant (p-value <
0.0001). The intercept was −0.034 which was not statisti-
cally significant (p-value 0.566). By Bland-Altman ana-
lysis (Fig. 4), the bias was 0.212 log copies/mL with 95 %
agreement intervals of −0.259 to 0.683.
Forty seven of 174 quantifiable by both assays were
subtype B, 99 subtype A, 11 Subtype C, 3 subtype G and
14 were CRFs.
Linear regression for subtype B is shown in Fig. 5. The
R2 was 0.968. The slope was 1.02 (Fig. 5) which was sta-
tistically not significant (p-value 0.384). The intercept
was 0.08 which was not statistically significant (p-value
0.494). By Bland-Altman analysis (Fig. 6) the bias was
0.179 log copies/mL with 95 % agreement intervals of
−0.258 to 0.617.
Linear regression for non-B subtypes is shown in Fig. 7.
The R2 was 0.972. The slope was 1.07 (Fig. 7) which was
statistically significant (p-value <0.0001). The intercept
was −0.07 which was not statistically significant (p-value
0.327). By Bland-Altman analysis (Fig. 8) the bias was
0.179 log copies/mL with 95 % agreement intervals of
−0.257 to 0.706.
Discussion
Detection and quantification of HIV-1 is important not
only for diagnosis of HIV-1 infections but also for
Table 1 Recovery of AcroMetrix subtype B Linearity Panel in
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management of HIV-1 patients [14]. High viral loads
are correlated with an increased risk of clinical progres-
sion of HIV-associated disease, and reductions in
plasma virus levels may be associated with decreased
risk of clinical progression [15–17]. To ensure the best
management of HIV positive patients it is important
that the test used to measure HIV-1 viral loads is sensi-
tive, specific, accurate and precise. As shown in this
study the Aptima assay on the Panther System is a
highly sensitive, specific and reproducible test for the
detection and quantitation of HIV-RNA across a wide
dynamic range.
As evident from the results of the AcroMetrix linearity
panel (Table 1) and dilutions of HIV subtype clinical
samples and isolates (Figs. 1 and 2) good linearity was
demonstrated across the assay range for all subtypes of
HIV in Aptima. The R 2 values for all the HIV groups
and subtypes tested were 0.999 or greater as shown in
Table 2. The HIV subtypes included A, B, C, AG, F1,
AE and G together with groups N and O. This shows
that the Aptima assay remains linear across a genetically
diverse sample population. This confirms the results
shown in the Aptima package insert [13] for HIV-1 groups
M, N and O.
The data presented in the package inserts for Roche
CAP/CTM [12] and Aptima [13] show the assays are
standardized to two different WHO standards (the 2nd
and 3rd lot of the WHO standard respectively). To en-
able a direct comparison of analytical sensitivity between
the two assays, the data on analytical sensitivity pre-
sented in this paper was based on dilutions of the 2nd
WHO international standard run in the Aptima assay.
The data is presented in IU/mL for this analysis to avoid
any issues converting between IU/mL to copies/mL for
assays standardized using two different WHO standards.
The 95 % limit of detection (LoD) of Aptima was found
to be 17.6 (95 % CI 15.2–21.2) IU/mL. This is slightly
more sensitive than the reported value for Roche CAP/
CTM assay at 33 IU/mL [12, 18]. The higher sensitivity
of Aptima compared to Roche CAP/CTM has been re-
ported by other investigators [19]. Table 7 shows 14
Aptima positive, Roche CAP/CTM negative results com-
pared to 11 Aptima negative, Roche CAP/CTM positive
results. Although this was not statistically significant it
suggests the Aptima assay is more sensitive than the
Fig. 1 Linearity of Aptima based on clinical specimens representing
different HIV subtypes
Fig. 2 Linearity of Aptima based on cultured isolates representing
different groups or subtypes of HIV
Table 2 R2 Values Linearity of Plots Aptima Based on Clinical
Specimens Representing Different HIV Groups or Subtypes










Table 3 Assessment of analytical sensitivity of Aptima HIV-1
Quant by dilutions of HIV-1 2nd international WHO standard
diluted in plasma
Panels IU/mL Number Number positive % Positive
0 89 0 0 %
5 89 46 52 %
10 90 73 81 %
15 90 84 93 %
20 90 88 98 %
25 89 87 98 %
30 90 89 99 %
40 89 89 100 %
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Roche CAP/CTM. The high sensitivity of the Aptima
assay indicates that it will be useful for both as an aid in
clinical management of and diagnosing patients with
HIV-1 infections.
It is also important for effective patient manage-
ment that the specificity of the assay is high. In this
study specificity was 99.83 % when testing 600 plasma
samples. A single sample from 600 gave a positive
result. The positive result was reported as “<30 cop-
ies/mL detected” and so was below the lower limit of
quantitation for the assay. Since the result was not
quantifiable it represents a very low level of HIV-1
between 1 and 30 copies/mL.
The subtype detection was evaluated using the NRC
subtype panel composed of 21 panel members targeted
at approximately 100,000 HIV-1 RNA copies/mL. The
isolates included subtype A, B, C, D, F, G and H as well
as circulating recombinants. Viral load results for the
Aptima assay were slightly higher than those for Roche
CAP/CTM but were within 0.5 log copies/mL in all
cases with one exception. This isolate which was a re-
combinant of G and H had a viral load result from
Aptima that was 0.79 log copies/mL higher than Roche
CAP/CTM. Abbott RT results were obtained for this
panel member which allow a comparison to be made to
a third assay. The Aptima result was within 0.27 logs of
the Abbott RT result. This suggests that the Roche
CAP/CTM result is low. Results for the remaining panel
members were available from the vendor for the Abbott
RT assay. The Aptima results were within 0.5 logs of the
Abbott RT result for 19 of the 21 samples. For 2 samples
the Abbott RT results were 0.51 (subtype H) and 1.04
(Group N) logs lower than Aptima. The Aptima result
was within 0.5 logs of the Roche CAP/CTM result for
the Group N sample suggesting that the Abbott RT re-
sult is low. Roche CAP/CTM results were unavailable
for the subtype H sample. This data confirms the results
in the Aptima package insert [13] showing equal HIV-1
group and subtype quantitation.
In the head to head comparison of Aptima and Roche
CAP/CTM high correlation was seen between the re-
sults in the two assays. The slope was 1.06 for all quanti-
fiable results. The Aptima assay gave slightly higher
results compared to Roche CAP/CTM at the higher
range of the assay and this contributed to the slope.
These differences are not clinically significant and are
similar to other studies [20, 21]. The average bias be-
tween Aptima and Roche CAP/CTM was 0.212 log
copies/mL which was mainly driven by higher Aptima
values at the higher range of the assay. This small bias is
not clinically significant. HIV subtype B is the most
prevalent subtype in Western Europe [22]. The clinical
specimen data set was broken into two subsets for fur-
ther analysis (subtype B samples and non subtype B
samples). Compared to Roche CAP/CTM, the Aptima
assay had a slope of 1.02 for subtype B and 1.07 for non-
subtype B samples. The Bland Altman plot showed a
slight positive bias for this data of 0.179 log copies/mL
for both sets of data but this is not clinically significant.
The higher slope seen for non subtype B compared to
subtype B suggests that the high proportion of non B
subtypes in the overall comparison to Roche CAP/CTM
contributed to the higher slope. In general the results in
Table 4 Assessment of analytical specificity of Aptima HIV-1
Quant Dx assay by two lots of HIV-1 negative samples
Reagent lot N Negative Specificity LCI UCI
lot 1 300 299 99.67 98.14 99.94
lot 2 300 300 100 98.74 100.00
Combined 600 599 99.83 99.06 99.97
Table 5 Assessment of inter-instrument, inter-operator, inter-lot, inter-day, inter-run, intra-run and total variability of Aptima HIV-1
Quant Dx in various HIV-1 RNA concentrations
Inter-instrument Inter-operator Inter-lot Inter-day Inter-run Intra-run Total














5E1 copies/mL 41a 1.66 0.075 4.52 0.033 1.99 0 0 0 0 0 0 0.119 7.12 0.144 8.67
1E2 copies/mL 74a 1.82 0 0 0 0 0.014 0.77 0 0 0.102 5.6 0.148 8.14 0.18 9.91
1E3 copies/mL 81 2.75 0.035 1.26 0 0 0 0 0 0 0.041 1.5 0.098 3.57 0.112 4.08
1E4 copies/mL 81 3.81 0.011 0.28 0.013 0.35 0 0 0.013 0.35 0.05 1.31 0.039 1.04 0.067 1.77
1E5 copies/mL 81 4.96 0.01 0.21 0 0 0 0 0 0 0.042 0.84 0.051 1.03 0.067 1.35
1E6 copies/mL 78b 6 0.008 0.14 0.001 0.02 0 0 0 0 0.048 0.79 0.027 0.44 0.055 0.92
1E7 copies/mL 81 6.89 0 0 0 0 0.026 0.38 0 0 0.033 0.47 0.046 0.67 0.062 0.9
Note: 1. Variability from some factors may be numerically negative, which can occur if the variability due to those factors is very small. When this occurs, SD = 0
and CV = 0 %
athe 50 and 100 copies/mL sample has lower N because some results were below the limit of quantification
b3 results were invalid and not included in the analysis
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this study are favorably compared with previous compar-
isons with the Aptima assay and assays such as Abbott
RealTime, Roche CAP/CTM, COBAS® TaqMan® HIV-1
Test v2.0 for use with the High Pure System (HPS/
CTM), Artus HIV-1 on the Qiagen Rotor-Gene Q and
Nuclisens EasyQ v2 (BioMerieux SA, Marcy L’Etoile,
France) [13, 23–25].
There are significant advantages when running the
Aptima assay for lab work flow. The Panther system is
fully automated so that samples can be placed directly
on the system without prior nucleic acid extraction. This
system allows random access testing of various analytes,
processing up to 320 samples in an 8-hour shift and







Aptima – Roche CAP/
CTM




92UG029 A 5.92 5.57 0.35 5.60 0.32
00KE_KER2018 A 5.11 4.98 0.13 5.02 0.09
92TH026 B 5.54 5.49 0.06 5.66 -0.12
90TH_BK132 B 5.57 5.37 0.21 5.36 0.21
92BR025 C 5.51 5.26 0.25 5.32 0.18
99ET_14 C 6.38 6.12 0.26 5.91 0.48
92UG021 D 5.47 5.45 0.03 5.51 -0.03
92UG035 D 6.02 5.61 0.40 5.77 0.25
92UG024 D 5.74 5.43 0.30 5.61 0.13
92TH022 CRF01_AE 5.25 not available not available 5.26 -0.01
92TH009 CRF01_AE 5.33 5.08 0.25 5.25 0.08
93BR029 F 5.15 5.16 0.01 5.18 -0.03
93BR020 F 5.59 not available not available 5.19 0.40
RU570 G 5.77 not available not available 5.70 0.08
VI557 H 5.95 not available not available 5.43 0.51
01CM.0005BBY CRF02_AG 4.89 4.77 0.12 4.68 0.21
01CM.0008BBY CRF02_AG 5.23 5.00 0.23 4.95 0.27
VI525 G/H 5.21 4.42 0.79 4.94 0.27
YBF 30 N 6.20 5.72 0.48 5.17 1.04
MVP5180 O 4.32 not available not available 4.23 0.09
CA-9 O 4.76 4.75 0.01 4.32 0.43




Roche CAP/CTM + 206 11 217
- 14 13 27
Total 220 24 244
The p-value for McNemar’s test is 0.5485 indicating that the difference in
positivity between Aptima and Roche for the type of samples tested is not
statistically significant
Fig. 3 Correlation between Aptima and Roche CAP/CTM in 174
samples quantified by both assays
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returning of results in about 2.5 hours. This enables
high flexibility to adapt to low or high throughput
testing. In addition, as reported by Sam et al. [21] the
cumulative hands-on time required for specimen pro-
cessing and maintenance steps were consistently
shorter with the Panther than with the Abbott m2000
system.
Conclusion
In conclusion, the Aptima assay has excellent compara-
tive performance with Roche CAP/CTM. The assay is a
good choice for clinicians in Europe for the detection
and monitoring of patients infected with HIV-1 as it has
CE–IVD certification. At present, the test is not ap-
proved for use in the US. The high sensitivity along with
Fig. 4 Bland Altman plot to assess the agreement between Aptima
HIV-1 Quant Dx and Roche CAP/CTM in 174samples quantified by both
assays
Fig. 5 Correlation between Aptima and Roche CAP/CTM for 47
samples quantified as subtype B by both assays
Fig. 6 Bland Altman plot to assess the agreement between Aptima
and Roche CAP/CTM in 47 subtype B samples quantified by
both assays
Fig. 7 Correlation between Aptima and Roche CAP/CTM in 127
samples of non-B subtype quantified by both assays
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close agreement to Roche CAP/CTM suggests re-
baseline of patients is not required when switching to
the Aptima assay for HIV-1 testing.
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